BOPA 2017 | Biosimilar benefits: cost saving in the NHS

Nicola Stoner • 6 Oct 2017

BOPA 2017

General

Biosimilar licensing represents a huge opportunity for the NHS to make vital cost savings. In this interview, recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Nicola Stoner, BSc, PhD, MRPharmS, SPresc, IPresc, FCPP from Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the recent approval of large molecule biosimilars, the cost saving benefits of these across the NHS and how this will benefit patients in the long term. Dr Stoner also references the national guidance and directives available to pharmacists for the introduction of biosimilars.